Company news
Ribomic, Inc. news in 2026
Ribomic, Inc.'s news releases, calls and decks from 2026, newest first.
RIBOMIC Enters into Technology Evaluation Agreement for DDS Aptamer Asset with a Foreign Biotech Company
October 20, 2026
RIBOMIC Announces Interim Report on the Phase 2 Long-Term Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
October 6, 2026
[Delayed]RIBOMIC Announces No Safety Concerns After Three Months of 1mg/kg Weekly Treatment with Umedaptanib Pegol in Achondroplasia Phase2 Study
September 29, 2026
RIBOMIC Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia
August 24, 2026
Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2026(Based on Japanese GAAP)
August 13, 2026
RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
July 1, 2026